HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

The nuclear factor erythroid 2-like 2 activator, tert-butylhydroquinone, improves cognitive performance in mice after mild traumatic brain injury.

Abstract
Traumatic Brain injury affects at least 1.7 million people in the United States alone each year. The majority of injuries are categorized as mild but these still produce lasting symptoms that plague the patient and the medical field. Currently treatments are aimed at reducing a patient's symptoms, but there is no effective method to combat the source of the problem, neuronal loss. We tested a mild, closed head traumatic brain injury model for the effects of modulation of the antioxidant transcription factor Nrf2 by the chemical activator, tert-butylhydroquinone (tBHQ). We found that post-injury visual memory was improved by a 7 day course of treatment and that the level of activated caspase-3 in the hippocampus was reduced. The injury-induced memory loss was also reversed by a single injection at 30 min after injury. Since the protective stress response molecule, HSP70, can be upregulated by Nrf2, we examined protein levels in the hippocampus, and found that HSP70 was elevated by the injury and then further increased by the treatment. To test the possible role of HSP70, model neurons in culture exposed to a mild injury and treated with the Nrf2 activator displayed improved survival that was blocked by the HSP70 inhibitor, VER155008. Following mild traumatic brain injury, there may be a partial protective response and patients could benefit from directed enhancement of regulatory pathways such as Nrf2 for neuroprotection.
AuthorsJ N Saykally, L Rachmany, H Hatic, A Shaer, V Rubovitch, C G Pick, B A Citron
JournalNeuroscience (Neuroscience) Vol. 223 Pg. 305-14 (Oct 25 2012) ISSN: 1873-7544 [Electronic] United States
PMID22890082 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, Non-P.H.S.)
CopyrightPublished by Elsevier Ltd.
Chemical References
  • Antioxidants
  • Glial Fibrillary Acidic Protein
  • HSP70 Heat-Shock Proteins
  • Hydroquinones
  • NF-E2-Related Factor 2
  • Nfe2l2 protein, mouse
  • Proto-Oncogene Proteins c-jun
  • Purine Nucleosides
  • RNA, Messenger
  • VER 155008
  • 2-tert-butylhydroquinone
  • Caspase 3
Topics
  • Analysis of Variance
  • Animals
  • Antioxidants (therapeutic use)
  • Avoidance Learning (drug effects)
  • Brain (metabolism, pathology)
  • Brain Injuries (complications, drug therapy)
  • Caspase 3 (genetics, metabolism)
  • Cell Line, Tumor
  • Cell Survival (drug effects)
  • Cognition Disorders (drug therapy, etiology, pathology)
  • Disease Models, Animal
  • Gene Expression Regulation (drug effects)
  • Glial Fibrillary Acidic Protein (genetics, metabolism)
  • HSP70 Heat-Shock Proteins (antagonists & inhibitors, genetics, metabolism)
  • Humans
  • Hydroquinones (therapeutic use)
  • Male
  • Maze Learning (drug effects)
  • Mice
  • Mice, Inbred ICR
  • Motor Activity (drug effects)
  • NF-E2-Related Factor 2 (metabolism)
  • Neuroblastoma (pathology)
  • Proto-Oncogene Proteins c-jun (genetics, metabolism)
  • Purine Nucleosides (pharmacology)
  • RNA, Messenger (metabolism)
  • Recognition, Psychology (drug effects)
  • Rotarod Performance Test
  • Time Factors

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: